血小板源性生长因子与血脑屏障的研究进展
Research Progress on Platelet-Derived Growth Factor and Blood-Brain Barrier
DOI: 10.12677/acm.2025.151040, PDF,    国家自然科学基金支持
作者: 汪怡孜：暨南大学附属第一医院神经内科，广东 广州；申 杰*：暨南大学附属东莞医院，东莞市滨海湾中心医院，神经内科，广东 东莞；深圳市龙岗区第三人民医院神经内科，广东 深圳
关键词: 血小板源性生长因子；血脑屏障；脑卒中；神经退行性疾病；Platelet-Derived Growth Factor； Blood Brain Barrier； Stroke； Neurodegenerative Diseases
摘要: 血脑屏障(blood brain barrier, BBB)是存在于外周血液和脑组织之间的结构，保护大脑免受内源性及外源性毒素和病原体的侵害，从而维持脑内环境稳定。在中枢神经系统疾病中，血脑屏障的破坏将进一步加剧疾病的进展。研究表明血小板源性生长因子(platelet-derived growth factor, PDGF)在血脑屏障的形成及功能维持中发挥重要作用，本文总结了PDGF及其受体在生理及病理情况下对血脑屏障的影响，初步探讨PDGF在中枢神经系统疾病中的治疗可能性，并对当前靶向PDGF及其受体的治疗手段进行简要综述。
Abstract: The blood brain barrier (BBB) is a structure that exists between peripheral blood and brain tissue, protecting the brain from endogenous and exogenous toxins and pathogens, thereby maintaining the stability of the brain internal environment. In central nervous system diseases, the disruption of BBB further exacerbates disease progression. Compelling data indicates that platelet-derived growth factor (PDGF) plays an important role in the maintenance and formation of BBB. This article summarizes the effects of PDGFs and their receptors on the integrity of BBB under physiological and pathological conditions. Finally, we briefly summarize the potential therapeutic strategy of PDGFs in central nervous system diseases, and review the current therapeutic methods targeting PDGFR.
文章引用：汪怡孜, 申杰. 血小板源性生长因子与血脑屏障的研究进展[J]. 临床医学进展, 2025, 15(1): 282-289. https://doi.org/10.12677/acm.2025.151040

参考文献

[1] Langen, U.H., Ayloo, S. and Gu, C. (2019) Development and Cell Biology of the Blood-Brain Barrier. Annual Review of Cell and Developmental Biology, 35, 591-613. [Google Scholar] [CrossRef] [PubMed]
[2] Kadry, H., Noorani, B. and Cucullo, L. (2020) A Blood-Brain Barrier Overview on Structure, Function, Impairment, and Biomarkers of Integrity. Fluids and Barriers of the CNS, 17, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[3] Liebner, S., Dijkhuizen, R.M., Reiss, Y., Plate, K.H., Agalliu, D. and Constantin, G. (2018) Functional Morphology of the Blood-Brain Barrier in Health and Disease. Acta Neuropathologica, 135, 311-336. [Google Scholar] [CrossRef] [PubMed]
[4] Iadecola, C. (2017) The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron, 96, 17-42. [Google Scholar] [CrossRef] [PubMed]
[5] Knox, E.G., Aburto, M.R., Clarke, G., Cryan, J.F. and O’Driscoll, C.M. (2022) The Blood-Brain Barrier in Aging and Neurodegeneration. Molecular Psychiatry, 27, 2659-2673. [Google Scholar] [CrossRef] [PubMed]
[6] Li, Y., Zhu, Z., Huang, T., Zhou, Y., Wang, X., Yang, L., et al. (2018) The Peripheral Immune Response after Stroke—A Double Edge Sword for Blood‐Brain Barrier Integrity. CNS Neuroscience & Therapeutics, 24, 1115-1128. [Google Scholar] [CrossRef] [PubMed]
[7] Hannink, M. and Donoghue, D.J. (1989) Structure and Function of Platelet-Derived Growth Factor (PDGF) and Related Proteins. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 989, 1-10. [Google Scholar] [CrossRef] [PubMed]
[8] Funa, K. and Sasahara, M. (2013) The Roles of PDGF in Development and during Neurogenesis in the Normal and Diseased Nervous System. Journal of Neuroimmune Pharmacology, 9, 168-181. [Google Scholar] [CrossRef] [PubMed]
[9] Kazlauskas, A. (2017) PDGFs and Their Receptors. Gene, 614, 1-7. [Google Scholar] [CrossRef] [PubMed]
[10] Sil, S., Periyasamy, P., Thangaraj, A., Chivero, E.T. and Buch, S. (2018) PDGF/PDGFR Axis in the Neural Systems. Molecular Aspects of Medicine, 62, 63-74. [Google Scholar] [CrossRef] [PubMed]
[11] Papadopoulos, N. and Lennartsson, J. (2018) The PDGF/PDGFR Pathway as a Drug Target. Molecular Aspects of Medicine, 62, 75-88. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, S.X.L., Gozal, D., Sachleben, L.R., Rane, M., Klein, J.B. and Gozal, E. (2003) Hypoxia Induces an Autocrine‐paracrine Survival Pathway via Platelet‐derived Growth Factor (PDGF)-B/PDGF‐β Receptor/phosphatidylinositol 3‐Kinase/Akt Signaling in RN46A Neuronal Cells. The FASEB Journal, 17, 1709-1711. [Google Scholar] [CrossRef] [PubMed]
[13] Tripathi, A., Parikh, Z.S., Vora, P., Frost, E.E. and Pillai, P.P. (2016) pERK1/2 Peripheral Recruitment and Filopodia Protrusion Augment Oligodendrocyte Progenitor Cell Migration: Combined Effects of PDGF-A and Fibronectin. Cellular and Molecular Neurobiology, 37, 183-194. [Google Scholar] [CrossRef] [PubMed]
[14] Đặng, T.C., Ishii, Y., Nguyen, V.D., Yamamoto, S., Hamashima, T., Okuno, N., et al. (2019) Powerful Homeostatic Control of Oligodendroglial Lineage by PDGFRα in Adult Brain. Cell Reports, 27, 1073-1089.e5. [Google Scholar] [CrossRef] [PubMed]
[15] Lindahl, P., Johansson, B.R., Levéen, P. and Betsholtz, C. (1997) Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice. Science, 277, 242-245. [Google Scholar] [CrossRef] [PubMed]
[16] Hellström, M., Kalén, M., Lindahl, P., Abramsson, A. and Betsholtz, C. (1999) Role of PDGF-B and PDGFR-β in Recruitment of Vascular Smooth Muscle Cells and Pericytes during Embryonic Blood Vessel Formation in the Mouse. Development, 126, 3047-3055. [Google Scholar] [CrossRef] [PubMed]
[17] Daneman, R., Zhou, L., Kebede, A.A. and Barres, B.A. (2010) Pericytes Are Required for Blood-Brain Barrier Integrity during Embryogenesis. Nature, 468, 562-566. [Google Scholar] [CrossRef] [PubMed]
[18] Lindblom, P., Gerhardt, H., Liebner, S., Abramsson, A., Enge, M., Hellström, M., et al. (2003) Endothelial PDGF-B Retention Is Required for Proper Investment of Pericytes in the Microvessel Wall. Genes & Development, 17, 1835-1840. [Google Scholar] [CrossRef] [PubMed]
[19] Smyth, L.C.D., Highet, B., Jansson, D., Wu, J., Rustenhoven, J., Aalderink, M., et al. (2022) Characterisation of PDGF-BB: PDGFRβ Signalling Pathways in Human Brain Pericytes: Evidence of Disruption in Alzheimer’s Disease. Communications Biology, 5, Article No. 235. [Google Scholar] [CrossRef] [PubMed]
[20] Nikolakopoulou, A.M., Zhao, Z., Montagne, A. and Zlokovic, B.V. (2017) Regional Early and Progressive Loss of Brain Pericytes but Not Vascular Smooth Muscle Cells in Adult Mice with Disrupted Platelet-Derived Growth Factor Receptor-Β Signaling. PLOS ONE, 12, e0176225. [Google Scholar] [CrossRef] [PubMed]
[21] Shen, J., Ishii, Y., Xu, G., Dang, T.C., Hamashima, T., Matsushima, T., et al. (2011) PDGFR-β as a Positive Regulator of Tissue Repair in a Mouse Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow & Metabolism, 32, 353-367. [Google Scholar] [CrossRef] [PubMed]
[22] Vazquez-Liebanas, E., Nahar, K., Bertuzzi, G., Keller, A., Betsholtz, C. and Mäe, M.A. (2021) Adult-Induced Genetic Ablation Distinguishes PDGFB Roles in Blood-Brain Barrier Maintenance and Development. Journal of Cerebral Blood Flow & Metabolism, 42, 264-279. [Google Scholar] [CrossRef] [PubMed]
[23] Li, X. and Eriksson, U. (2003) Novel PDGF Family Members: PDGF-C and PDGF-D. Cytokine & Growth Factor Reviews, 14, 91-98. [Google Scholar] [CrossRef] [PubMed]
[24] Fang, L., Yan, Y., Komuves, L.G., Yonkovich, S., Sullivan, C.M., Stringer, B., et al. (2004) PDGF C Is a Selective α Platelet-Derived Growth Factor Receptor Agonist That Is Highly Expressed in Platelet Α Granules and Vascular Smooth Muscle. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 787-792. [Google Scholar] [CrossRef] [PubMed]
[25] Tang, Z., Arjunan, P., Lee, C., Li, Y., Kumar, A., Hou, X., et al. (2010) Survival Effect of PDGF-CC Rescues Neurons from Apoptosis in Both Brain and Retina by Regulating GSK3β Phosphorylation. Journal of Experimental Medicine, 207, 867-880. [Google Scholar] [CrossRef] [PubMed]
[26] Fredriksson, L., Li, H., Fieber, C., Li, X. and Eriksson, U. (2004) Tissue Plasminogen Activator Is a Potent Activator of PDGF-CC. The EMBO Journal, 23, 3793-3802. [Google Scholar] [CrossRef] [PubMed]
[27] Lee, C., Zhang, F., Tang, Z., Liu, Y. and Li, X. (2013) PDGF-C: A New Performer in the Neurovascular Interplay. Trends in Molecular Medicine, 19, 474-486. [Google Scholar] [CrossRef] [PubMed]
[28] Su, E.J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., et al. (2008) Activation of PDGF-CC by Tissue Plasminogen Activator Impairs Blood-Brain Barrier Integrity during Ischemic Stroke. Nature Medicine, 14, 731-737. [Google Scholar] [CrossRef] [PubMed]
[29] Folestad, E., Kunath, A. and Wågsäter, D. (2018) PDGF-C and PDGF-D Signaling in Vascular Diseases and Animal Models. Molecular Aspects of Medicine, 62, 1-11. [Google Scholar] [CrossRef] [PubMed]
[30] Lee, C. and Li, X. (2018) Platelet-derived Growth Factor-C and-D in the Cardiovascular System and Diseases. Molecular Aspects of Medicine, 62, 12-21. [Google Scholar] [CrossRef] [PubMed]
[31] Liu, C., Zhao, W., Meng, W., Zhao, T., Chen, Y., Ahokas, R.A., et al. (2014) Platelet-Derived Growth Factor Blockade on Cardiac Remodeling Following Infarction. Molecular and Cellular Biochemistry, 397, 295-304. [Google Scholar] [CrossRef] [PubMed]
[32] Feigin, V.L., Brainin, M., Norrving, B., Martins, S., Sacco, R.L., Hacke, W., et al. (2022) World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke, 17, 18-29. [Google Scholar] [CrossRef] [PubMed]
[33] Abdullahi, W., Tripathi, D. and Ronaldson, P.T. (2018) Blood-Brain Barrier Dysfunction in Ischemic Stroke: Targeting Tight Junctions and Transporters for Vascular Protection. American Journal of Physiology-Cell Physiology, 315, C343-C356. [Google Scholar] [CrossRef] [PubMed]
[34] Jiang, X., Andjelkovic, A.V., Zhu, L., Yang, T., Bennett, M.V.L., Chen, J., et al. (2018) Blood-Brain Barrier Dysfunction and Recovery after Ischemic Stroke. Progress in Neurobiology, 163, 144-171. [Google Scholar] [CrossRef] [PubMed]
[35] Krupinski, J., Issa, R., Bujny, T., Slevin, M., Kumar, P., Kumar, S., et al. (1997) A Putative Role for Platelet-Derived Growth Factor in Angiogenesis and Neuroprotection after Ischemic Stroke in Humans. Stroke, 28, 564-573. [Google Scholar] [CrossRef] [PubMed]
[36] Su, E.J., Cao, C., Fredriksson, L., Nilsson, I., Stefanitsch, C., Stevenson, T.K., et al. (2017) Microglial-Mediated PDGF-CC Activation Increases Cerebrovascular Permeability during Ischemic Stroke. Acta Neuropathologica, 134, 585-604. [Google Scholar] [CrossRef] [PubMed]
[37] Nguyen, Q.L., Okuno, N., Hamashima, T., Dang, S.T., Fujikawa, M., Ishii, Y., et al. (2020) Vascular PDGFR-α Protects against BBB Dysfunction after Stroke in Mice. Angiogenesis, 24, 35-46. [Google Scholar] [CrossRef] [PubMed]
[38] He, Q., Ma, Y., Fang, C., Deng, Z., Wang, F., Qu, Y., et al. (2023) Remote Ischemic Conditioning Attenuates Blood-Brain Barrier Disruption after Recombinant Tissue Plasminogen Activator Treatment via Reducing PDGF-CC. Pharmacological Research, 187, Article ID: 106641. [Google Scholar] [CrossRef] [PubMed]
[39] Ma, Q., Huang, B., Khatibi, N., Rolland, W., Suzuki, H., Zhang, J.H., et al. (2011) PDGFR‐α Inhibition Preserves Blood‐brain Barrier after Intracerebral Hemorrhage. Annals of Neurology, 70, 920-931. [Google Scholar] [CrossRef] [PubMed]
[40] Shibahara, T., Ago, T., Nakamura, K., Tachibana, M., Yoshikawa, Y., Komori, M., et al. (2020) Pericyte-Mediated Tissue Repair through PDGFRβ Promotes Peri-Infarct Astrogliosis, Oligodendrogenesis, and Functional Recovery after Acute Ischemic Stroke. eNeuro, 7, ENEURO.0474-19.2020. [Google Scholar] [CrossRef] [PubMed]
[41] Shen, J., Xu, G., Zhu, R., Yuan, J., Ishii, Y., Hamashima, T., et al. (2018) PDGFR-β Restores Blood-Brain Barrier Functions in a Mouse Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow & Metabolism, 39, 1501-1515. [Google Scholar] [CrossRef] [PubMed]
[42] Nakamura, K., Arimura, K., Nishimura, A., Tachibana, M., Yoshikawa, Y., Makihara, N., et al. (2016) Possible Involvement of Basic FGF in the Upregulation of PDGFRβ in Pericytes after Ischemic Stroke. Brain Research, 1630, 98-108. [Google Scholar] [CrossRef] [PubMed]
[43] Antoniou, G., Lee, A.T.J., Huang, P.H. and Jones, R.L. (2018) Olaratumab in Soft Tissue Sarcoma—Current Status and Future Perspectives. European Journal of Cancer, 92, 33-39. [Google Scholar] [CrossRef] [PubMed]
[44] Rieckmann, P. (2008) Imatinib Buys Time for Brain after Stroke. Nature Medicine, 14, 712-713. [Google Scholar] [CrossRef] [PubMed]
[45] Wahlgren, N., Thorén, M., Höjeberg, B., Käll, T., Laska, A., Sjöstrand, C., et al. (2016) Randomized Assessment of Imatinib in Patients with Acute Ischaemic Stroke Treated with Intravenous Thrombolysis. Journal of Internal Medicine, 281, 273-283. [Google Scholar] [CrossRef] [PubMed]
[46] Gagalo, I., Rusiecka, I. and Kocic, I. (2015) Tyrosine Kinase Inhibitor as a New Therapy for Ischemic Stroke and Other Neurologic Diseases: Is There Any Hope for a Better Outcome? Current Neuropharmacology, 13, 836-844. [Google Scholar] [CrossRef] [PubMed]
[47] Adzemovic, M., Zeitelhofer, M., Eriksson, U., Olsson, T. and Nilsson, I. (2013) Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response. PLOS ONE, 8, e56586. [Google Scholar] [CrossRef] [PubMed]
[48] Paul, G., Zachrisson, O., Varrone, A., Almqvist, P., Jerling, M., Lind, G., et al. (2015) Safety and Tolerability of Intracerebroventricular PDGF-BB in Parkinson’s Disease Patients. Journal of Clinical Investigation, 125, 1339-1346. [Google Scholar] [CrossRef] [PubMed]
[49] Han, L. and Jiang, C. (2021) Evolution of Blood–brain Barrier in Brain Diseases and Related Systemic Nanoscale Brain-Targeting Drug Delivery Strategies. Acta Pharmaceutica Sinica B, 11, 2306-2325. [Google Scholar] [CrossRef] [PubMed]
[50] Haney, M.J., Klyachko, N.L., Zhao, Y., Gupta, R., Plotnikova, E.G., He, Z., et al. (2015) Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy. Journal of Controlled Release, 207, 18-30. [Google Scholar] [CrossRef] [PubMed]
[51] Tian, T., Zhang, H., He, C., Fan, S., Zhu, Y., Qi, C., et al. (2018) Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy. Biomaterials, 150, 137-149. [Google Scholar] [CrossRef] [PubMed]
[52] Rajput, A., Varshney, A., Bajaj, R. and Pokharkar, V. (2022) Exosomes as New Generation Vehicles for Drug Delivery: Biomedical Applications and Future Perspectives. Molecules, 27, Article 7289. [Google Scholar] [CrossRef] [PubMed]
[53] Blesa, J., Pineda-Pardo, J.A., Inoue, K., Gasca-Salas, C., Balzano, T., Del Rey, N.L., et al. (2023) BBB Opening with Focused Ultrasound in Nonhuman Primates and Parkinson’s Disease Patients: Targeted AAV Vector Delivery and PET Imaging. Science Advances, 9, eadf4888. [Google Scholar] [CrossRef] [PubMed]

为你推荐